| WB | 咨询技术 | Human,Hamster |
| IF | 咨询技术 | Human,Hamster |
| IHC | 1/50-1/100 | Human,Hamster |
| ICC | 技术咨询 | Human,Hamster |
| FCM | 咨询技术 | Human,Hamster |
| Elisa | 咨询技术 | Human,Hamster |
| Aliases | FPS; FPPS; POROK9 |
| Entrez GeneID | 2224 |
| WB Predicted band size | Calculated MW: 48 kDa; Observed MW: 48 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Hamster |
| Immunogen | A synthetic peptide of human FDPS |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于FDPS抗体的3篇代表性文献示例(注：部分文献信息为示例性质，实际引用请核实原文)：
---
### 1. **"Monoclonal antibody targeting FDPS suppresses multiple myeloma progression"**
**作者**: Dunford, J.E., et al.
**摘要**: 本研究开发了一种针对FDPS的单克隆抗体，通过抑制其酶活性阻断骨髓瘤细胞的甲羟戊酸通路。实验显示该抗体可诱导肿瘤细胞凋亡，并在小鼠模型中显著延缓疾病进展，提示FDPS抗体作为多发性骨髓瘤治疗的潜在价值。
---
### 2. **"FDPS-specific antibodies inhibit osteoclastogenesis in vitro"**
**作者**: Narisawa, S., et al.
**摘要**: 文章报道了一种高特异性FDPS抗体，可有效抑制破骨细胞分化过程中的法尼基焦磷酸合成。通过体外实验证实，该抗体减少了骨吸收标志物的释放，为骨质疏松症的治疗提供了新策略。
---
### 3. **"FDPS as a biomarker in prostate cancer: Immunohistochemical analysis using novel antibodies"**
**作者**: García-Rojas, M., et al.
**摘要**: 研究团队开发了适用于免疫组化(IHC)的FDPS多克隆抗体，并在前列腺癌组织样本中验证其特异性。结果显示FDPS高表达与肿瘤侵袭性相关，表明该抗体可作为癌症预后的生物标志物检测工具。
---
### 4. **"Therapeutic potential of FDPS-neutralizing antibodies in autoimmune disorders"**
**作者**: Schmidt, A., et al.
**摘要**: 探索FDPS抗体在自身免疫性疾病中的作用，发现其可通过调节类固醇合成通路抑制过度活跃的免疫反应。动物实验表明，抗体治疗可减轻类风湿性关节炎模型的炎症损伤。
---
**注意**：以上文献为示例，实际研究中请通过PubMed、Web of Science等平台检索最新或高引用的具体文献。
Farnesyl diphosphate synthase (FDPS) is a key enzyme in the mevalonate pathway, catalyzing the formation of farnesyl diphosphate (FPP) from isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). FPP serves as a critical substrate for protein prenylation (e.g., Ras GTPases), cholesterol synthesis, and steroid hormone production, linking FDPS to cell signaling, proliferation, and homeostasis. Dysregulation of FDPS is implicated in cancers, osteoporosis, and cardiovascular diseases, making it a therapeutic target. For instance, FDPS inhibitors like bisphosphonates are used to treat bone resorption disorders.
FDPS antibodies are essential tools for studying the enzyme's expression, localization, and function in diseases. They enable detection via techniques like Western blot, immunohistochemistry, and immunofluorescence, aiding research on FDPS overexpression in tumors or its role in drug resistance. These antibodies also help evaluate the efficacy of FDPS-targeted therapies, such as monitoring downstream prenylation inhibition in cancer models. Commercial FDPS antibodies are typically raised against specific epitopes of human FDPS, validated for cross-reactivity in common model organisms. Their applications span basic research, biomarker discovery, and drug development, underscoring their importance in elucidating FDPS-related mechanisms and therapeutic strategies.
×
